Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML

This study is testing a three-drug combination — chiglitazar sodium (a metabolic drug), venetoclax (a drug that triggers cancer cell death), and azacitidine (a chemotherapy drug) — for patients with acute myeloid leukemia (AML) that has returned or stopped responding to treatment. **You may be eligible if...** - You are 18 years of age or older - You have been confirmed to have AML that is relapsed (came back after remission) or refractory (never achieved remission) - This includes secondary AML arising from other blood conditions - Your kidney and liver function are adequate - You are expected to survive at least 3 months **You may NOT be eligible if...** - You have not tried at least one prior treatment - Your organ function is too poor to tolerate the treatment - You have serious infections or other conditions that make participation unsafe Talk to your doctor to see if this trial is right for you.